Compare Bristol-Myers Squibb Co (BMY) vs Innovative Industrial Properties Inc (IIPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Innovative Industrial Properties Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.63 (market cap $129.94B), while Innovative Industrial Properties Inc trades at $58.2 (market cap $1.67B). The key difference: Bristol-Myers Squibb Co is far larger — about 77.8× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays the higher dividend (13.18%). Which is the better fit depends on your goals.
| BMY | IIPR | |
|---|---|---|
Market Cap | $129.94B | $1.67B |
Sector | Health | Real Estate |
52-Week High | $65.89 | $64.67 |
52-Week Low | $42.60 | $44.58 |
Enterprise Value | $163.92B | $2.21B |
Dividend Yield | 3.96% | 13.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
IIPR trades at $57.69, showing modest daily gains of 0.37%. The stock presents mixed signals with bearish technical indicators but strong fundamentals including a P/E of 13.05 and net margin of 52.27%. Recent Q2 2026 earnings beat expectations with $1.36 EPS versus $1.02 forecast. The company maintains robust cash flow from operations at $198.19M and recently declared a $1.90 dividend for H1-2026.
Outlook remains cautiously optimistic despite technical weakness. The 9.09% dividend yield and attractive valuation metrics provide support, but declining revenue from $266M (2025) to $264M (2026) and tenant concentration risks in the cannabis REIT sector warrant monitoring. Analyst consensus leans Hold (54.55%) with institutional interest growing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →
